Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:7
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview
    Matson, Johnny L.
    Neal, Daniene
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2009, 30 (03) : 572 - 586
  • [22] Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: A nationwide outpatient service study, 1997-2007
    Hsu, Shang-Wei
    Chiang, Po-Huang
    Chang, Yu-Chia
    Lin, Jin-Ding
    Tung, Ho-Jui
    Chen, Chao-Yun
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2014, 35 (02) : 364 - 372
  • [23] Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour
    Deb, S.
    Unwin, G.
    Deb, T.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2015, 59 (01) : 11 - 25
  • [24] Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure
    Brett, Jonathan
    Karanges, Emily A.
    Daniels, Benjamin
    Buckley, Nicholas A.
    Schneider, Carl
    Nassir, Atheer
    Zoega, Helga
    McLachlan, Andrew J.
    Pearson, Sallie-Anne
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 (10) : 990 - 999
  • [25] Psychotropic drug use among people with intellectual disability before and after deinstitutionalization
    Nottestad, JA
    Linaker, OM
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2003, 47 : 464 - 471
  • [26] The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach
    Niven, Abigail
    Goodey, Rebecca
    Webb, Alison
    Shankar, Rohit
    BRITISH JOURNAL OF LEARNING DISABILITIES, 2018, 46 (01) : 4 - 9
  • [27] Rational Use and Rationale for Use: Psychiatric Medication at an Argentine Institution for Intellectual Disability
    de Menil, Victoria
    Cohen, Alex
    TRANSCULTURAL PSYCHIATRY, 2009, 46 (04) : 651 - 671
  • [28] Relation between resilience and cigarette/alcohol use in adolescents with mild intellectual disability
    Pavlovic, Miroslav
    Zunic-Pavlovic, Vesna
    Glumbic, Nenad
    VOJNOSANITETSKI PREGLED, 2019, 76 (03) : 259 - 265
  • [29] A cross-sectional study of recent patterns of psychotropic medication use in children and adolescents in Ireland
    Parkin, Rebecca
    Bennett, Kathleen
    Mc Nicholas, Fiona
    Hayden, John C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, 47 (01) : 146 - 156
  • [30] Health and wellbeing of people with intellectual disability in New South Wales, Australia: a data linkage cohort
    Reppermund, Simone
    Heintze, Theresa
    Srasuebkul, Preeyaporn
    Reeve, Rebecca
    Dean, Kimberlie
    Smith, Melinda
    Emerson, Eric
    Snoyman, Phillip
    Baldry, Eileen
    Dowse, Leanne
    Szanto, Tracey
    Sara, Grant
    Florio, Tony
    Johnson, Anina
    Clements, Melissa
    McKenzie, Kathryn
    Trollor, Julian
    BMJ OPEN, 2019, 9 (09):